Pilgrim claims that its integrated risk, compliance and quality management solution helps regulated organisations remain compliant, recognise and preemptively address potential operational dangers, reduce costs, and operate more
Dapagliflozin Phase 3 study also showed that Dapagliflozin plus glimepiride achieved reductions in the secondary efficacy endpoints of change in total body weight, oral glucose tolerance test (OGTT)
As per the terms of a special arrangement, the antibodies are being provided at low cost to the entire PD research community to help advance LRRK2 therapeutic development
Designed specifically for clinicians, the CF-H1 Mobile Clinical Assistant tablet, is a lightweight, shock and water-resistant, tablet computing device that can be easily disinfected and allows doctors and
The multi-center study is being conducted by Inovio’s clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080. Earlier, Inovio reported
Zynex, a provider of pain management systems and electrotherapy medical devices, said that a provisional patent has been filed for the application, which could serve a currently untapped
Tacrolimus capsules is an immunosuppressant. It blocks the action of certain blood cells (eg, T lymphocytes) that can cause the body to reject the transplanted organ. Mylan Pharma’s
The filing triggers a milestone payment to Lausanne, Switzerland-based drug delivery company EffRx. Nycomed and EffRx entered into the licensing agreement for EX101 in early 2009 and Nycomed
Biomagnetics Diagnostics has signed the formal merger agreement and all necessary governmental approvals are expected to be completed mid-week. Biomagnetics CEO Clayton Hardman said that they have selected
As per the agreement, Access will ensure manufacturing capacity of up to a minimum of $30m of product in the licensed territories. Access has also approved a sub-license
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.